Bioscience

ABRAXANE in combination with gemcitabine increases survival in Phase I/II study

April 19, 2010

By Flinn Foundation

[Source: Pipeline Review] – Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced updated overall survival findings from a phase I/II study of nab®-paclitaxel given in combination with gemcitabine, demonstrated increased survival of the first-line treatment of patients with advanced pancreatic cancer. In 44 patients treated at the recommended dose of 125 mg/m2 nab-paclitaxel plus gemcitabine, the median overall survival (OS) time was 12.2 months, a doubling of survival compared to historical control of gemcitabine administered alone.i This combination of nab-paclitaxel and gemcitabine also resulted in a confirmed overall response rate in 50 percent of patients treated, and a disease control rate of 68 percent. In the overall study (n=67), three patients achieved a complete response. These findings were discussed during a keynote address by Daniel Von Hoff, M.D., “Epithelium and Stroma: Double Trouble,” during the “Progress in Pancreatic Cancer” session on April 18 at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

For more information: ABRAXANE in Combination with Gemcitabine Increases Survival in First-Line Treatment of Advanced Pancreatic Cancer in Phase I/II Study